{"name":"Guangzhou Bio-gene Technology Co., Ltd","slug":"guangzhou-bio-gene-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BAFFR CAR-T","genericName":"BAFFR CAR-T","slug":"baffr-car-t","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_1"}]}],"pipeline":[{"name":"BAFFR CAR-T","genericName":"BAFFR CAR-T","slug":"baffr-car-t","phase":"phase_1","mechanism":"CAR-T cell therapy targeting BAFFR","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"pipeline","source":"GlobeNewswire","summary":"CAR T-Cell Therapy Market to Hit USD 13.78 Billion by 2031, - GlobeNewswire","headline":"CAR T-Cell Therapy Market to Hit USD 13.78 Billion by 2031,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNMHdBejQwLTZFSl8tZDVNdXJ3V2MwYmxUdnQ1bWoydl9ELXlUR2M5SXIzZlBDWFFEb3gtU1RmTXI1Nk8zNGhjNGdGcXVoN3lHNFBkTEtPTkh1ZFk2cVBOY0hlbzlNVGg2ZFAxTDN4bXA0aUZoMzNMUVNnSEZxamcyemhLSzJrRlZ1LWJNVW1hWDB3LVBMcnpnb0pSamR5SkNFYmxkOEtQRGFzZ3RoWEJxWXFhZmNUd3l0SFpQM1Utd1QwTHBfNmtv?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire","summary":"CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™ - PR Newswire","headline":"CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWk5QY1A2c0Ryc0dobWlGYk1rdUZpQnVNeXQ4NWh2RENmMXh2UjNzcXJXU1piVEstcElUSk82Q2ZXUFhDaHo4SE1uamJBdDJ5LWFoTHZ2UUNTdFB0b3ZuNzUxaXlyMVU3SnFobTdlOFBwZzRrTVlJVHZVV2M1UTZSWThfMngtS1pFRVJr?oc=5","date":"2025-12-04","type":"trial","source":"Yahoo Finance","summary":"Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Yahoo Finance","headline":"Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Dom","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-10","type":"deal","source":"BioSpace","summary":"Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License A","headline":"Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Ref","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPMlJzdE1mR2hBOUhxMFZ1RUJBcEhCUGZ3Smthd2hkRFZ0cl9UWl95N3RQQXhxemRHYlBGb2RpbHlIWm9PcWFCeGZkaTRIeHA1dlp5V1RrN3U3LUxMek1pYmhMalhuVG5tZUhXdzRXYWJLNktfYVY0UWJUWGRha043MjQxSEtwVVdxMFlzX25qTDJWSHNFeXNKTVZKeWQxZnFoQ0dj?oc=5","date":"2025-07-17","type":"pipeline","source":"BioWorld News","summary":"34 mainland China biotechs file for Hong Kong IPO in H1 2025 - BioWorld News","headline":"34 mainland China biotechs file for Hong Kong IPO in H1 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdGJiX1hIRnBfajZ4OUVpTXN3X1RHTUNnT1RLdUFOSGlGbHN5NjVnbll1a1h4UEVpNjNHcURnUF9xb1pVM2pwX2JVVFlnWHh6SU9LOFh3U0Zwd1FXZmxpVXpvbHZtcGRhTU14YmxudmF3azRzckJlYUpvZ2dlN2NJbTFPYkdIaTFLVHhOTTZBZWRSNlB5LTQ5UnJOeHlGeUpaVTkwNERUYi02blpuUHhPdjhBZ3p6NTRLTlNLdFZ5Slh6YVlCblhXTGdzYjNEMHMwY0ZwZDV0MDBoU3p5V1RQTnpHb1I1NUJmTGotckNWZzQwSFdTVUdYaFc4S29yWWc5Q1pnTTZib1VxLTRHSmUzbUprc0c1OEdpN2JtZzd1MUxLMm1SNDhjMERR?oc=5","date":"2025-07-07","type":"trial","source":"GlobeNewswire","summary":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum: - GlobeNewswire","headline":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZGb1d4SlV6bHhTQ0RSVURidk9lekxZR0JyZlM1OEFCcmNBcnpaNGZCZzdybERwZFNjb2VSSjJmWXJpdUMwbWMxZW93ZXY0SV8wUDRBSVRaaFRxeFpPNXFCZ3JqQUpwbEtWdFNEY2lPYURISVF2QmV4aG8zdmw0dlpxV0RFT3VnV29fRmdkdDd3WkVrM1VJaU5rb0J3aHdGbkhGeE0yRFM4clBOQWxGT0JaTFcxS3VlVHZzNHU1YjlhQlEtcG1OUjlzdEp1QjU5RlNBeXNlcHZJLVl6SVBONkdkTQ?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire","headline":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQZUxKUEg5OVdyclNkSjJhRENXeWlJOElSb19EeVJPeDFuZDl0MWprYkh1ck1Wb0g1SUVsVkN6RDlORldaWHFmeDNiMWoycU1UTjlvMFlaMlZJS1E4d0JtT3lDcW52YTZiNXBSY0VxNW5BZ1lzQ2E1VXpTaVpEeDVIYlhIWUhXTzkzYURsWWc1LTM?oc=5","date":"2024-06-27","type":"trial","source":"Clinical Trials Arena","summary":"CAR T cells in lupus: Promising results at EULAR 2024 and emergence of China - Clinical Trials Arena","headline":"CAR T cells in lupus: Promising results at EULAR 2024 and emergence of China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPQVdzNTI2dmMtX2hFQlB1aGpqTWNoUDY2R0dzLXpuQVV1ZWdNTERzTzNtVUVkc01HVDJyYWQzYUlvUVVqM0pBV0FmOHBKeUg0LW9qM3hPQ1dLYzVjVlJIN3NoOFJkLVU4WElrS05uMGF0bTBvSUZ4R3RNcGl6LXVEYU0wUEhmc0JMRW9QcUN3S0FBbXBmSzl1WmxIUHFzN3NpakM0YWlidVZTRWNNQ3RQd01YR3lXTnplTU9ZQ0hJTjRtdWFJS1M1cnNDb0Yta2dzcDB1bFhGRlpsZldMN2FWMUNiQjh0aTU3YXpvY1NsMA?oc=5","date":"2023-11-08","type":"regulatory","source":"CRISPR Medicine News","summary":"Press Release Service: CD19-Targeting Therapies Show Remarkable Growth, Revolutionizing Cancer Treatment with High Response Rates - ResearchAndMarkets.com - CRISPR Medicine News","headline":"Press Release Service: CD19-Targeting Therapies Show Remarkable Growth, Revolutionizing Cancer Treatment with High Respo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQOFk3dXFBUERSX3Z6Z2xvRElhRC0xNThEeGhkSUNVbVJ5b29wbzY2dXlsRTB0Y0xtQ1BPVGlweWNuZWpvRVZlQzUyc3N6Q2x2YXJSNnlVaWxlTGp3UnBUSk5iX1dlSTlsT2owSHFuQ0Z6aFIweFN6S3dMVDlkZnZ4UHdRQQ?oc=5","date":"2023-03-09","type":"pipeline","source":"DCAT Value Chain Insights","summary":"The CDMO/CMO Report: Cell and Gene Therapies - DCAT Value Chain Insights","headline":"The CDMO/CMO Report: Cell and Gene Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQR05HU0xncUdQYW1iWXFLUXRYY3czdVVWSkdoR2JfbkVEcmNFa0RjRTlKQ2tMcVp4ZFVwUjVYWjRPQ19FWldpRmZtVkFPdUxsTmdXRUdERnQzS3daVWY1N2s5MDExNXNnMVVyWGxBdnBnX3JQZUV0V0VwRGZyUlFYbUp3U2xIM1hFSFJsOUR5Y0h1bklRY1dqbTlfWVVqY0N1?oc=5","date":"2022-04-14","type":"pipeline","source":"Fierce Pharma","summary":"VectorBuilder to spend $500M to construct gene therapy manufacturing site in China - Fierce Pharma","headline":"VectorBuilder to spend $500M to construct gene therapy manufacturing site in China","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}